

<u>Day</u>	<u>Time</u>	<u>Speaker</u>	<u>Title</u>	<u>Affiliation</u>
Monday	24 Sept.		Fragment Finding	
	7:00 AM		Breakfast opens	
	8:00 AM	Rod Hubbard	Current Perspectives in FBLD	Vernalis / University of York
	8:30 AM	Jane Withka	Building Confidence for Chemistry by Generation of a Quality Library and a Multidisciplinary Approach	Pfizer
	9:00 AM	Nino Campobasso	Picking up the fragments at GlaxoSmithKline: No longer a last chance effort for lead ID	GlaxoSmithKline
	9:20 AM	Peter Kutchukian	Privileged Substructures for Fragment-Based Screening	Novartis
	9:40 AM		Question and Answer session	
	9:55 AM		Tea and coffee break, posters, and exhibitors	
	10:25 AM	Josh Salafsky	Second-harmonic generation (SHG) for allosteric and conformation-specific drug discovery: conformational change in real time	Biodesy
	10:45 AM	Dallas Hughes	Fragment Screening using Capillary Electrophoresis (CEfragTM): Complementing Existing Biophysical and Structural Methods for Drug Discovery	Selcia
	11:05 AM	Sten Ohlson	Introducing weak affinity chromatography (WAC; affinity LC-MS) as a new approach for fragment screening	Linnaeus University
	11:25 AM	Fredrik Rahm	Validating Thermal Shift Assays for Fragment Screening	Sprint
	11:45 AM		Question and Answer session	
	12:00 PM		Lunch, posters, and exhibitors	
	1:30 PM	Charles Wartchow	Biosensor-based Lead Identification and Hit Confirmation in Fragment Screening Campaigns with Protein-Protein Interaction Targets	Roche
	1:50 PM	Karin Regnstrom	Label free fragment screening using Surface Plasmon Resonance as a Tool for Fragment Finding: Analyzing difficult CNS targets for binding activity, selectivity, and non-specific interactions.	Elan
	2:10 PM	Helena Danielson	Developing the tools for discovery of fragment-based leads for membrane bound targets	Beactica
	2:30 PM	Miles Congreve	Fragment Based Drug Discovery for G Protein-Coupled Receptors	Heptares
	3:00 PM	Pamela Williams	Fragment identification using X-rays: the advantages of structural certainty	Astex
	3:30 PM		Question and Answer session	
	3:45 PM		Tea and coffee break, posters, and exhibitors	
	4:15 PM	Parag Sahasrabudhe	Discovery of a Novel Fragment Inhibitor of Acetyl CoA Carboxyltransferase	Pfizer
Tuesday	25 Sept.		Fragment to Lead	
	7:00 AM		Breakfast opens	
	8:00 AM	Tom Peat	The many sites of HIV integrase: a fragment screening odyssey	CSIRO
	8:20 AM	Darren Begley	Multi-Target Fragment Screening & Structure Determination in the MEP Pathway	Emerald
	8:40 AM	Sarah Barelrier	Parallel Fragment-Screening and Docking against AmpC β -lactamase	UCSF
	9:00 AM	Kathryn Loving	Recent Advances in Structure-Based Fragment Docking and Virtual Screening	Schrödinger
	9:30 AM		Question and Answer session	
	9:45 AM		Tea and coffee break, posters, and exhibitors	
	10:15 AM	Man-ling Lee	Fragment Screening Hit Triage: Advantages of Order Dependent Clustering Using a new Similarity Metric	Genentech
	10:35 AM	JW Feng	ROCS Your Fragment Hits with Interactive 3D Similarity Search	Genentech
	10:55 AM	Carsten Detering	Supporting the Drug Discovery Pipeline: Fragment-Based Compound Manipulation and Accurate Scoring	BioSolveIT
	11:15 AM	Sandor Vajda	Computational protein mapping to drive the development of fragment hits into leads	Boston University
	11:45 AM		Question and Answer session	
	12:00 PM		Lunch, posters, and exhibitors	
	1:30 PM	Lars Neumann	Application of kinetic and thermodynamic parameters in FBLD	Proteros
	1:50 PM	James Murray	From the (k)off: The prospective use of the dissociation rate constant to guide Fragment 2 Leads Chemistry	Vernalis
	2:20 PM	Yu Chen	Fragment-based inhibitor discovery against CTX-M Class A β -lactamase	U South Florida
	2:40 PM	Adam Renslo	Reversible, Non-Electrophilic Inhibitors of CTX-M Class A β -Lactamase: From Fragments to Cell-Active Leads	UCSF
	3:00 PM		Question and Answer session	
	3:15 PM		Tea and coffee break, posters, and exhibitors	
	3:45 PM	Christopher Stubbs	Allosteric Targeting of Polo-like Kinase 1: A Fragment-Based Approach	Cambridge University
Wednesday	26 Sept.		Success Stories	
	7:00 AM		Breakfast opens	
	8:00 AM	Anders Friberg	Cancer Drug Discovery Using Fragment-Based Methods	Vanderbilt University
	8:30 AM	Andrew Petros	Attacking Apoptosis with Fragments	Abbott
	9:00 AM	Wolfgang Jahnke	Tuning bone affinity into fragment-derived leads	Novartis
	9:30 AM		Tea and coffee break	
	10:00 AM	Ivan Efremov	Fragments vs. BACE: use of fragment-based approached to enable a tough target	Pfizer
	10:30 AM	Daniel Wyss	FBDD on a tough target starts to yield – Discovery of orally active, brain penetrant BACE1 inhibitors	Merck
	11:00 AM	Chao Zhang	Scaffolds among Fragments: Searching for a Multi-faceted Progenitor of Kinase Inhibitors	Plexxikon
	11:30 AM		Closing comments	
	12:00 PM		End of conference	